221 Whitney Avenue
PO BOX 208202
23 articles with Yale University
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Algernon Pharmaceuticals Inc. is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement (“CTA”) with Yale University (“Yale”) for the investigation of multiple intravenous doses of DMT for the treatment of depression.
If replicated in humans, this technology could prolong organ health during major surgeries and improve the availability of donor organs.
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.
With Spring comes new beginnings, and companies within the biopharmaceutical industry are blossoming with fresh ventures. Here are some of them:
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy
Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for Cancer Research Annual Meeting in New Orleans on April 8-13, 2022.
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here's how this consortium will help researchers.
Revealed in an article published in Science magazine, this new variant of HIV was discovered in individuals in the Netherlands, Belgium and Switzerland.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
A team of researchers has developed an mRNA-based Lyme vaccine that aims to prevent Lyme disease by deterring the tick itself. And here's how effective it is.
Autism Changes Brain's White Matter over Time
Researchers at Yale University analyzing specialized MRI exams found significant changes in the microstructure of the brain's white matter in adolescents and young adults with autism spectrum disorder compared to a control group, according to research being presented next week at the annual meeting of the Radiological Society of North America.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Clinical-stage biopharmaceutical company, Aptorum Group Limited, announced today that it has entered into a material transfer and option agreement with Yale University to study preclinical stage novel immunomodulators targeting autoimmune and oncology diseases.
D&D Pharmatech Announces Sponsored Research Agreement with Yale University to Optimize Novel Strategies for the Treatment of Brain Cancer and Other Diseases of the Central Nervous System
VEGF-C shown to circumvent barriers in the brain’s lymphatic system; combination of VEGF-C and a checkpoint inhibitor promoted anti-tumor response and extended survival in preclinical model of glioblastoma
Candel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
Candel Therapeutics, a clinical-stage biotechnology company developing novel immune-based cancer therapeutics, announced the initial formation of its Research Advisory Board with the appointment of James Allison, Ph.D., Henry Brem, M.D., Roy S. Herbst, M.D., Ph.D., Elizabeth Jaffee, M.D., Philip Kantoff, M.D., and Padmanee Sharma, M.D., Ph.D., who will join existing scientific advisor and board member Edward Benz, M.D.
Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs
Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
Technology Innovation Institute’s Cryptography Research Centre in Abu Dhabi Collaborates with Yale University
Partnership aims to pioneer breakthroughs in post-quantum cryptography and neuromorphic computing, leading to effective research outcomes and a knowledge-driven ecosystem in Abu Dhabi and the UAE
First Large-scale Study Finds Child Care Is Not Associated With Spread Of Covid-19
Yale University Study Found No Association Between Child Care and the Spread of COVID-19 to Providers; Child Care Aware of America Provides Recommendations for Providers, Parents and Policymakers